Oculis to Present at Upcoming May Investor Conferences

Core Insights - Oculis Holding AG is a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs [5] Upcoming Conferences - Oculis will present at several investor conferences, including Bio€quity Europe from May 12-14, 2025, where CEO Riad Sherif will provide a company update on May 14 at 11am CET [1] - The company will also participate in the Bank of America Healthcare Conference from May 13-15, 2025, featuring a fireside chat with CFO Sylvia Cheung on May 14 at 3pm PT [2] - Additional presentations include the H.C. Wainwright Annual BioConnect at Nasdaq on May 20, 2025, and the Stifel Virtual Ophthalmology Forum on May 27, 2025, both featuring updates from CFO Sylvia Cheung [2] Company Pipeline - Oculis has a differentiated pipeline that includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME); Privosegtor (OCS-05), a neuroprotective candidate for acute optic neuritis; and Licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED) [5]